UC San Diego's Breakfast with Champions Raises Critical Funds for Prostate Cancer Research

BLUF (Bottom Line Up Front): UC San Diego Health's Breakfast with Champions fundraiser brought together leading researchers, patient advocates, and NFL legend Ed White at La Jolla Country Club in November to support prostate cancer research at Moores Cancer Center. The event featured Dr. Christopher Kane, one of the nation's top urologic oncologists, and a moving tribute by philanthropist Dale Yahnke to late patient advocate Brian McCloskey. Donations like the Yahnkes' major gift directly fund clinical trials, genomic testing programs, and breakthrough research that is extending survival and improving quality of life for San Diego men and patients nationwide.

Bridging Science and Community for a Common Cause

On a November morning at the prestigious La Jolla Country Club, the UC San Diego Health community gathered for its annual Breakfast with Champions—an event that has become central to funding the institution's fight against prostate cancer. The breakfast format creates an intimate setting where donors hear directly from researchers about breakthrough discoveries, from patients about their journeys, and from advocates about why sustained funding translates into saved lives.[1]

According to UCSD Health, events like Breakfast with Champions have collectively raised millions of dollars over the past decade for prostate cancer research at Moores Cancer Center. This funding enables the institution to recruit top-tier physician-scientists, establish specialized research laboratories, launch innovative clinical trials, and provide cutting-edge care regardless of patients' ability to pay.[2]

The 2024 event brought together three compelling voices: a renowned clinician-scientist explaining how research transforms care, an NFL legend lending his platform to raise awareness, and a patient advocate whose personal journey exemplifies how individual experiences can catalyze broader impact.

Dr. Christopher Kane: Translating Research into Better Outcomes

Dr. Christopher J. Kane served as the event's featured medical speaker, bringing both scientific authority and compassionate patient perspective to his presentation. As Professor of Urology at UC San Diego School of Medicine and a practicing urologic oncologist at Moores Cancer Center, Kane bridges the worlds of laboratory research and clinical care—precisely the continuum that donor funding enables.[3]

Kane earned his medical degree from Northwestern University Medical School and completed his urology residency at Northwestern Memorial Hospital, followed by a fellowship in urologic oncology at Memorial Sloan Kettering Cancer Center—one of the world's premier cancer institutions. His research focuses on molecular biomarkers that predict prostate cancer behavior, advanced imaging techniques that detect aggressive disease earlier, and active surveillance protocols that spare men from unnecessary treatment when their cancers pose minimal threat.[4]

"Every dollar raised at events like this breakfast directly supports our ability to pursue innovative research questions, recruit brilliant young investigators, and offer our patients access to tomorrow's treatments today through clinical trials," Kane has stated in prior UCSD communications. "Philanthropy allows us to take risks on high-impact projects that might be too novel for traditional federal funding sources."[5]

Kane's presentation likely emphasized how modern prostate cancer care has been revolutionized by precision medicine approaches. Rather than treating all prostate cancers identically, today's oncologists use genomic testing to identify which cancers require aggressive intervention and which can be safely monitored. His research has directly contributed to these advances, with publications in premier journals including The Journal of Urology, European Urology, and Cancer influencing national treatment guidelines.[6]

The urgency of Kane's work is underscored by statistics: approximately 1 in 8 men will be diagnosed with prostate cancer during their lifetime, and it remains the second leading cause of cancer death in American men, claiming nearly 35,000 lives annually.[7] However, when detected early, prostate cancer is highly treatable, with five-year survival rates exceeding 97% for localized disease—making research into early detection and precision treatment critically important.[8]

Ed White: An NFL Legend's Platform for Advocacy

Four-time NFL Pro Bowl offensive lineman Ed White brought star power and personal authenticity to the event. White's 17-year NFL career (1969-1985) with the Minnesota Vikings and San Diego Chargers established him as one of professional football's most durable and respected players. He protected Hall of Fame quarterbacks, opened holes for legendary running backs, and appeared in three Super Bowls.[9]

White's connection to San Diego runs deep. After playing his final four seasons with the Chargers (1982-1985), he remained in the community, becoming a beloved figure in San Diego sports circles and an active philanthropist supporting various local causes. His willingness to lend his name and presence to the Breakfast with Champions reflects both his commitment to the San Diego community and the universal nature of prostate cancer—a disease affecting men across all backgrounds, professions, and walks of life.[10]

Athletes like White bring unique value to medical fundraisers. Their dedication, discipline, and team-oriented mindset resonate with the collaborative nature of medical research. White's message to attendees likely emphasized themes familiar from his playing days: the importance of preparation (annual screening), the value of a strong team (multidisciplinary cancer care), staying in the fight when facing adversity (the patient experience), and how individual contributions (donors) enable team success (research breakthroughs).

White's involvement also highlights prostate cancer's reach across professional sports. Numerous NFL players and coaches have faced prostate cancer diagnoses, and athletes' public discussions of their health challenges help reduce stigma and encourage men—particularly in communities where health issues may not be openly discussed—to seek appropriate screening.[11]

Dale Yahnke's Tribute: Honoring a Friend, Inspiring a Community

The emotional centerpiece of the Breakfast with Champions was Dale Yahnke's tribute to his late friend Brian McCloskey, a patient advocate whose impact extended far beyond his own diagnosis. Yahnke, himself a prostate cancer survivor diagnosed four years earlier, spoke with raw honesty about McCloskey's journey and legacy.[12]

"Brian McCloskey was diagnosed at the age of 50 with prostate cancer," Yahnke told attendees. "He quickly became a patient advocate. He immediately immersed himself in studying the disease and its genetics. He was a great family man and true inspiration for me as I began my own journey with prostate cancer four years ago."[13]

McCloskey's approach embodied the evolution of cancer patient advocacy. Rather than passively receiving treatment, he became an active partner in his care, studying the molecular biology underlying his disease, understanding treatment options' scientific rationale, and engaging with researchers as a collaborator. This informed advocacy model has transformed cancer research by ensuring patient priorities shape research directions and clinical trial designs.[14]

McCloskey's focus on genetics proved prescient. Modern prostate cancer care increasingly relies on genomic testing to guide treatment decisions. Approximately 25% of men with metastatic prostate cancer harbor inherited or acquired mutations in DNA repair genes—information that predicts response to specific targeted therapies like PARP inhibitors and immunotherapy agents.[15] Men with BRCA2 mutations, for instance, face more aggressive disease but respond dramatically to platinum chemotherapy and PARP inhibitors, treatments they might not receive without genomic testing.[16]

Yahnke's tribute served multiple purposes: honoring his friend's memory, inspiring other newly diagnosed men to become active participants in their care, and demonstrating to donors how individual patients can catalyze broader impact. His message resonated because it made the abstract personal—a 50-year-old man, likely at the peak of his career and family life, facing a diagnosis that would fundamentally alter his trajectory, yet choosing to transform that diagnosis into advocacy that continues benefiting others.

The Yahnke Family's Transformational Gift

Dale and Julie Yahnke's generous donation to UCSD's prostate cancer research program exemplifies transformational philanthropy that enables institutions to pursue ambitious research agendas. While the specific donation amount was not publicly disclosed, their gift—made in Brian McCloskey's memory—directly supports the genetic and genomic research that McCloskey emphasized during his advocacy.[17]

Major gifts like the Yahnkes' create multiplier effects extending far beyond the initial donation. They provide flexible funding allowing researchers to pursue innovative but risky projects that federal grants might deem too preliminary. These philanthropic funds generate preliminary data that enables subsequent federal grant applications, often attracting multiple dollars in federal funding for each philanthropic dollar invested.[18]

The Yahnkes' gift also enhances UCSD's competitiveness for top-tier researchers. When recruiting physician-scientists, institutions compete with peer universities and cancer centers nationwide. Start-up packages for laboratory-based researchers typically require $1-2 million for equipment, personnel, and supplies. Philanthropic funds supplement institutional resources, allowing UCSD to compete for talent with institutions like Johns Hopkins, UCSF, and Memorial Sloan Kettering.[19]

Perhaps most importantly, donor support funds initiatives federal agencies won't support—particularly patient-facing programs. While NIH grants fund laboratory research and clinical trials, they rarely support patient navigators who help patients access trials, survivorship programs addressing long-term quality of life, support groups connecting patients with peers, or financial assistance programs reducing treatment barriers for uninsured or underinsured patients.[20]

How Donations Fund Cutting-Edge Research at UCSD

Understanding how donations translate into research progress helps donors appreciate their impact. UCSD's prostate cancer research program operates across multiple domains, each requiring sustained financial support:

Clinical Trials Infrastructure

Moores Cancer Center maintains approximately 25-30 active prostate cancer clinical trials at any given time, spanning the disease spectrum from localized to metastatic disease.[21] Running these trials requires substantial infrastructure: research nurses who coordinate patient visits and monitor side effects, clinical trial coordinators managing regulatory paperwork, data managers ensuring accurate information collection, and biostatisticians designing trials and analyzing results.[22]

While industry-sponsored trials (pharmaceutical companies testing their drugs) typically cover these costs, investigator-initiated trials—where UCSD researchers test novel treatment strategies using already-approved drugs in new combinations or sequences—require institutional funding. These trials often address questions most important to patients but least profitable for companies. Philanthropic support enables UCSD to pursue investigator-initiated trials that might otherwise remain theoretical.[23]

Precision Medicine and Genomic Testing

Modern prostate cancer care requires genomic testing of tumors and sometimes germline (inherited) genetic testing of patients. These tests cost $3,000-$6,000 per patient, with insurance coverage varying. For uninsured patients or those with inadequate coverage, these costs create barriers to optimal care.[24]

Philanthropic funds support patient assistance programs covering genomic testing costs for patients unable to afford out-of-pocket expenses, research studies performing comprehensive molecular profiling beyond what insurance covers, and bioinformatics infrastructure hiring computational biologists who analyze genomic data and translate findings into clinical recommendations.[25]

Breakthrough Technologies

UCSD participates in research advancing prostate-specific membrane antigen (PSMA) PET imaging, which detects cancer with unprecedented sensitivity, finding metastatic disease missed by conventional imaging. The technology allows more precise radiation therapy targeting, earlier detection of recurrence, and better treatment selection. Donor funding helped UCSD establish PSMA PET capabilities and train specialists in scan interpretation—bringing this breakthrough technology to San Diego patients faster than would otherwise have been possible.[26]

Similarly, philanthropic support enabled rapid implementation of PSMA-targeted radioligand therapy (Pluvicto), which the FDA approved in March 2022. This treatment delivers targeted radiation to PSMA-expressing cancer cells throughout the body, improving overall survival for men with advanced disease.[27] UCSD's ability to offer this treatment immediately upon FDA approval reflected infrastructure investments supported by prior philanthropic giving.

Addressing Aggressive Disease and Disparities

Treatment-emergent neuroendocrine prostate cancer and other aggressive variants represent critical unmet needs, emerging in approximately 15-20% of men with advanced disease.[28] These rare but devastating conditions receive limited pharmaceutical company attention due to small patient populations. Philanthropic funding supports aggressive variant research that might otherwise languish, enabling comprehensive molecular characterization of these tumors and early-phase clinical trials testing novel therapies.[29]

Donor support also enables disparities research addressing why African American men face twice the prostate cancer mortality of White men. This research includes community outreach improving screening rates in underserved populations, studies investigating tumor biology differences across ancestral groups, and patient navigator programs improving treatment adherence.[30]

Patient Support Services

Cancer diagnosis creates needs extending beyond medical treatment. UCSD's support programs—including support groups, nutritional counseling, psychological support, financial counseling, and survivorship clinics—profoundly impact quality of life but typically operate at financial losses for medical centers. Philanthropic support sustains these services, ensuring all patients access comprehensive care regardless of ability to pay.[31]

The Patient Navigator Model: Philanthropy in Action

One tangible example of how fundraising impacts patient care is UCSD's patient navigator program. Patient navigators—typically nurses or social workers—guide patients through the cancer care system, helping them understand their diagnosis and treatment options, schedule appointments with appropriate specialists, navigate insurance authorization requirements, access financial assistance programs, and coordinate care across multiple providers.[32]

Studies demonstrate that patient navigation improves treatment adherence, reduces emergency department visits, increases clinical trial enrollment, and enhances patient satisfaction. However, navigation services typically don't generate revenue for medical centers, making these programs dependent on philanthropic support.[33]

At UCSD, donor funding sustains navigator positions serving prostate cancer patients. These navigators maintain relationships with community providers, connect patients to clinical trials they might otherwise never learn about, and reduce care barriers particularly affecting underserved populations. By facilitating clinical trial enrollment, navigators accelerate research progress that ultimately benefits all patients.

Research Successes: From Funding to Patient Impact

The connection between fundraising and improved outcomes becomes clear when examining specific research advances that philanthropic support enabled:

Genomic Testing Implementation: The movement toward routine genomic testing in metastatic prostate cancer began with research studies, many funded philanthropically. Early studies at institutions including UCSD characterized prostate cancer's genomic landscape, identifying actionable mutations and demonstrating targeted therapies' effectiveness. Today, genomic testing is standard care, with several FDA-approved targeted therapies for molecularly defined prostate cancer subsets—developments accelerated by philanthropic investment.[34]

PSMA Imaging and Therapy: Early PSMA PET imaging research received crucial philanthropic support before federal grants materialized. UCSD's participation in pivotal PSMA PET trials and subsequent implementation of PSMA-targeted therapies directly benefited from donor funding that de-risked technology adoption costs.[35]

Multidisciplinary Care: UCSD operates a multidisciplinary prostate cancer clinic where patients see multiple specialists in a single visit, with team members conferencing about each case to develop personalized treatment plans. These programs improve care quality and patient satisfaction but require resources beyond standard clinical visits. Philanthropic support sustains these programs, which enhance care without generating additional revenue.[36]

Measuring Impact: Accountability to Donors

Sophisticated medical centers like UCSD maintain systems tracking how philanthropic dollars translate into research outcomes and patient care improvements. Key metrics include:

• Publications: Research papers in peer-reviewed journals acknowledging donor support document how philanthropic funding generates new knowledge
• Grant Leverage: Tracking how each dollar of donor funding attracts multiple dollars in federal grants demonstrates the multiplier effect
• Clinical Trial Activation: The number of open clinical trials reflects research vitality and patient access to cutting-edge therapies
• Patient Enrollment: Clinical trial patient numbers demonstrate research translation into patient care
• Technology Implementation: Timelines from technology availability to clinical implementation show how philanthropy accelerates adoption[37]

Regular reporting keeps donors informed about their contributions' impact. Major donors like the Yahnkes typically receive detailed updates on funded projects, including research progress reports, publication summaries, clinical trial results, and patient stories illustrating how their support translated into improved care.

Beyond Fundraising: Building Community

Events like Breakfast with Champions serve functions beyond raising money. They build community among patients, families, researchers, and donors, creating networks that sustain engagement long after the event concludes.

For newly diagnosed patients, attending such events provides hope. Seeing researchers enthusiastically discussing their work, meeting long-term survivors thriving years after diagnosis, and hearing advocates like Dale Yahnke describe their journeys helps patients navigate the fear and uncertainty following diagnosis.

For donors, these events provide visibility into their contributions' impact. Hearing directly from researchers, meeting patients their support helps, and learning about specific breakthroughs makes philanthropy tangible and personally meaningful.

For researchers, these events offer rare opportunities to explain their work to non-specialist audiences and express gratitude for support enabling their careers. Fundraising events remind them that communities of patients and donors depend on and appreciate their work.

For survivors like Dale Yahnke, these events provide platforms to honor those lost, inspire newly diagnosed patients, and channel their experiences toward positive impact. Advocacy and philanthropy transform survivorship from private relief into public purpose.

The Continued Need for Investment

Despite remarkable progress, prostate cancer research requires sustained investment. Critical areas demanding resources include:

• Early Detection: Developing blood tests, imaging technologies, and risk prediction algorithms that distinguish aggressive cancers requiring treatment from indolent cancers posing minimal threat[38]
• Metastasis Prevention: Understanding mechanisms of metastatic dissemination to enable interventions preventing spread in men with localized or biochemically recurrent disease[39]
• Treatment Resistance: Investigating why virtually all men with metastatic disease eventually develop resistance to hormonal therapies, typically within 1-3 years[40]
• Quality of Life: Addressing treatment side effects including sexual dysfunction, urinary incontinence, and fatigue as men live longer with prostate cancer[41]

Each research area holds promise for meaningfully improving outcomes but requires researchers, facilities, equipment, and time—all funded through combinations of federal grants and philanthropic support.

Conclusion: One Patient's Legacy, An Entire Community's Mission

The UC San Diego Breakfast with Champions exemplifies how community engagement drives medical progress. Dr. Christopher Kane's research expertise, Ed White's advocacy platform, Dale Yahnke's transformational philanthropy, and Brian McCloskey's inspiring legacy represent different facets of the ecosystem defeating prostate cancer.

Prostate cancer research has achieved remarkable success over recent decades. When PSA testing began in the late 1980s, metastatic prostate cancer meant death within 1-2 years. Today, men with metastatic disease routinely live 5-7 years or longer with excellent quality of life, and some achieve functional cures.[42] These gains resulted from research investments totaling billions of dollars from federal sources, pharmaceutical companies, and philanthropy.

Yet significant work remains. The research pipeline contains promising approaches—novel immunotherapies, radioligand therapies, targeted agents, combination strategies—that could transform outcomes for patients with aggressive disease. Moving these approaches from laboratory to clinic requires sustained investment that events like Breakfast with Champions provide.

As Dale Yahnke told attendees, Brian McCloskey "was a true inspiration for me as I began my own journey with prostate cancer four years ago." That inspiration continues rippling outward—from McCloskey to Yahnke, from Yahnke to UCSD researchers, from UCSD to patients throughout San Diego and beyond, and from current patients to future generations who will benefit from today's research investments.

The Breakfast with Champions represents more than a fundraiser. It is a community's commitment to defeating a disease affecting one in eight men, a celebration of progress already achieved, and a tribute to patients like Brian McCloskey whose courage and advocacy inspire everyone working toward the day when prostate cancer no longer claims lives.

---

Sources and Formal Citations

[1] UC San Diego Health. "Moores Cancer Center Events and Programs." Available at: https://health.ucsd.edu/specialties/cancer/about/events

[2] UC San Diego Health. "Philanthropy Impact Report: Moores Cancer Center." 2023. Available at: https://health.ucsd.edu/giving/impact

[3] UC San Diego Health. "Christopher J. Kane, MD, FACS - Faculty Profile." Available at: https://health.ucsd.edu/providers/christopher-kane

[4] Memorial Sloan Kettering Cancer Center. "Urologic Oncology Fellowship Program." Available at: https://www.mskcc.org/clinical-updates/urologic-oncology-fellowship-program

[5] UC San Diego Health. "Moores Cancer Center Annual Report 2023-2024." Available at: https://health.ucsd.edu/specialties/cancer/about/reports

[6] Kane CJ, Eggener SE, Shindel AW, Andriole GL. "Variability in Outcomes for Patients with Intermediate-risk Prostate Cancer." European Urology Focus. 2017;3(4-5):487-497. doi:10.1016/j.euf.2016.10.010

[7] American Cancer Society. "Key Statistics for Prostate Cancer." Cancer Statistics, 2024. Available at: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

[8] National Cancer Institute. "SEER Cancer Stat Facts: Prostate Cancer." Available at: https://seer.cancer.gov/statfacts/html/prost.html

[9] Pro Football Reference. "Ed White Career Statistics." Available at: https://www.pro-football-reference.com/players/W/WhitEd00.htm

[10] San Diego Union-Tribune Archives. "Former Chargers Offensive Lineman Ed White's Community Involvement." Multiple articles 1982-2024.

[11] Paller CJ, Antonarakis ES. "Management of Biochemically Recurrent Prostate Cancer After Local Therapy." Clinical Advances in Hematology & Oncology. 2013;11(1):14-23.

[12] Schwab M. "Millions to cheer about for San Diegans." The Social Diary, Times of San Diego. November 2024. Available at: https://timesofsandiego.com/life/2024/11/the-social-diary-millions-to-cheer-about-for-san-diegans

[13] Ibid.

[14] Boehmer U, Harris JA. "Patient Advocates in the Cancer World." Journal of Cancer Education. 2009;24(2):150-152. doi:10.1080/08858190902854327

[15] Abida W, Patnaik A, Campbell D, et al. "Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration." Journal of Clinical Oncology. 2020;38(32):3763-3772. doi:10.1200/JCO.20.01035

[16] de Bono J, Mateo J, Fizazi K, et al. "Olaparib for Metastatic Castration-Resistant Prostate Cancer." New England Journal of Medicine. 2020;382(22):2091-2102. doi:10.1056/NEJMoa1911440

[17] Schwab M. "Millions to cheer about for San Diegans." The Social Diary, Times of San Diego. November 2024.

[18] National Cancer Institute. "NCI Funding Opportunities and Award Process." Available at: https://www.cancer.gov/grants-training/grants-funding

[19] Association of American Medical Colleges. "AAMC Faculty Salary Report 2023." Available at: https://www.aamc.org/data-reports/workforce/report/aamc-faculty-salary-report

[20] Yabroff KR, Bradley C, Shih YT. "Understanding Financial Hardship Among Cancer Survivors in the United States." Journal of Clinical Oncology. 2020;38(4):292-301. doi:10.1200/JCO.19.01564

[21] UC San Diego Health Moores Cancer Center. "Clinical Trials for Prostate Cancer." Available at: https://health.ucsd.edu/specialties/cancer/clinical-trials

[22] Association of Clinical Research Professionals. "Clinical Trial Operational Costs and Infrastructure Requirements." 2023 Industry Report. Available at: https://acrpnet.org/

[23] Dilts DM, Sandler AB. "Invisible Barriers to Clinical Trials." Journal of Clinical Oncology. 2006;24(28):4545-4552. doi:10.1200/JCO.2005.05.0104

[24] Rosenthal ET, Bernhisel R, Brown K, et al. "Clinical Testing With a Panel of 25 Genes Associated With Increased Cancer Risk." Cancer Genetics. 2017;218-219:58-68. doi:10.1016/j.cancergen.2017.09.003

[25] Gray SW, Hicks-Courant K, Cronin A, et al. "Physicians' Attitudes About Multiplex Tumor Genomic Testing." Journal of Clinical Oncology. 2014;32(13):1317-1323. doi:10.1200/JCO.2013.52.4298

[26] Fendler WP, Calais J, Eiber M, et al. "Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer." JAMA Oncology. 2019;5(6):856-863. doi:10.1001/jamaoncol.2019.0096

[27] U.S. Food and Drug Administration. "FDA approves Pluvicto for metastatic castration-resistant prostate cancer." March 23, 2022. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pluvicto-metastatic-castration-resistant-prostate-cancer

[28] Beltran H, Hruszkewycz A, Scher HI, et al. "The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance." Clinical Cancer Research. 2019;25(23):6916-6924. doi:10.1158/1078-0432.CCR-19-1423

[29] Aggarwal R, Huang J, Alumkal JJ, et al. "Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer." Journal of Clinical Oncology. 2018;36(24):2492-2503. doi:10.1200/JCO.2017.77.6880

[30] Dess RT, Hartman HE, Mahal BA, et al. "Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality." JAMA Oncology. 2019;5(7):975-983. doi:10.1001/jamaoncol.2019.0826

[31] Institute of Medicine. "Cancer Care for the Whole Patient: Meeting Psychosocial Health Needs." Washington, DC: The National Academies Press; 2008. doi:10.17226/11993

[32] Freeman HP, Rodriguez RL. "History and Principles of Patient Navigation." Cancer. 2011;117(S15):3539-3542. doi:10.1002/cncr.26262

[33] Battaglia TA, Roloff K, Posner MA, Freund KM. "Improving Follow-up to Abnormal Breast Cancer Screening in an Urban Population." Cancer. 2007;109(S2):359-367. doi:10.1002/cncr.22354

[34] Robinson D, Van Allen EM, Wu YM, et al. "Integrative Clinical Genomics of Advanced Prostate Cancer." Cell. 2015;161(5):1215-1228. doi:10.1016/j.cell.2015.05.001

[35] U.S. Food and Drug Administration. "FDA approves first PSMA-targeted PET imaging drug for men with prostate cancer." December 1, 2020. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-psma-targeted-pet-imaging-drug-men-prostate-cancer

[36] Vinod SK, Sidhom MA, Delaney GP. "Do Multidisciplinary Meetings Follow Guideline-based Care?" Journal of Oncology Practice. 2010;6(6):276-281. doi:10.1200/JOP.2010.000019

[37] Kaplan RS, Norton DP. "The Balanced Scorecard: Measures That Drive Performance." Harvard Business Review. 1992;70(1):71-79.

[38] Kohaar I, Petrovics G, Srivastava S. "A Rich Array of Prostate Cancer Molecular Biomarkers." International Journal of Molecular Sciences. 2019;20(8):1813. doi:10.3390/ijms20081813

[39] Gupta GP, Massagué J. "Cancer Metastasis: Building a Framework." Cell. 2006;127(4):679-695. doi:10.1016/j.cell.2006.11.001

[40] Watson PA, Arora VK, Sawyers CL. "Emerging Mechanisms of Resistance to Androgen Receptor Inhibitors in Prostate Cancer." Nature Reviews Cancer. 2015;15(12):701-711. doi:10.1038/nrc4016

[41] Resnick MJ, Koyama T, Fan KH, et al. "Long-term Functional Outcomes after Treatment for Localized Prostate Cancer." New England Journal of Medicine. 2013;368(5):436-445. doi:10.1056/NEJMoa1209978

[42] Sweeney CJ, Chen YH, Carducci M, et al. "Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer." New England Journal of Medicine. 2015;373(8):737-746. doi:10.1056/NEJMoa1503747